K.G. reports no conflicts of interest. S.K. has received honoraria from Miltenyi, Galapagos, Cymab, Novartis, Plectonic, TCR2 Inc., Bristol Myers Squibb, and GlaxoSmithKline, and is listed as an inventor on several immuno-oncology patents. S.K. has also received license fees from TCR2 Inc. and Carina Biotech, as well as research support from TCR2 Inc., Tabby Therapeutics, Catalym GmbH, Plectonic GmbH, and Arcus Bioscience for work not related to the present manuscript.